BeOne Medicines at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
BeOne Medicines exhibits at Booth 421 at ASH 2026 in New Orleans. Its presence centres on chronic lymphocytic leukemia, supporting symposia on patient priorities, targeted therapies and how investigators manage the disease. It also supports symposia on BTK inhibitor options in mantle cell lymphoma and community oncologists' questions about novel lymphoma therapies.
| Organization | ASH 2026 Attendance |
|---|---|
BeOne Medicines Basel, Switzerland | |
Global oncology company, formerly BeiGene, whose medicines include the BTK inhibitor zanubrutinib for CLL and other B-cell cancers. | Booth Exhibiting at Booth 421 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. |
Instantly find 20 buyers from BeOne Medicines
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction